Jove
Visualize
Contact Us

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.0K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.5K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.5K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.5K
Stem Cell Therapy for Tissue Regeneration01:21

Stem Cell Therapy for Tissue Regeneration

4.4K
Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
4.4K
Tumor Immunotherapy01:27

Tumor Immunotherapy

816
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
816
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

624
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
624

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

RNAs anchoring replication complex control initiation and firing of DNA replication.

Nature communications·2026
Same author

The C/EBPα-(PU.1-LOUP) regulatory circuit regulates monocyte/macrophage development and immune functions.

Blood·2026
Same author

Small activating RNA AW1-51 (CEBPA-51) elicits targeted DNA demethylation to promote gene activation.

bioRxiv : the preprint server for biology·2025
Same author

An Upstream RUNX3 Enhancer, eR3 (-18m/-28h), Regulates the Development of Gut-Associated Anti-Tumorigenic CD8<sup>+</sup>CD103<sup>+</sup> Cytotoxic T Lymphocytes in Mouse and Human.

Genes to cells : devoted to molecular & cellular mechanisms·2025
Same author

Targeting transcription factors through an IMiD independent zinc finger domain.

EMBO molecular medicine·2025
Same author

Posttranscriptional activity of the eukaryotic translation initiation factor eIF4E contributes to HoxA9-driven leukemogenesis.

bioRxiv : the preprint server for biology·2025
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Nov 10, 2025

Author Spotlight: Exploring the Lifespan Dynamics of Healthy Human Hematopoiesis
03:40

Author Spotlight: Exploring the Lifespan Dynamics of Healthy Human Hematopoiesis

Published on: December 8, 2023

1.5K

Emerging therapies for inv(16) AML.

Sridevi Surapally1, Daniel G Tenen2,3, John A Pulikkan1,4

  • 1Program in Stem Cell Biology and Hematopoiesis, Versiti Blood Research Institute, Milwaukee, WI.

Blood
|April 6, 2021
PubMed
Summary

Core binding factor beta-smooth muscle myosin heavy chain (CBFβ-SMMHC) fusion oncogene drives acute myeloid leukemia (AML) with inv(16). This review explores its mechanisms and therapeutic strategies for inv(16) AML.

More Related Videos

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

421
Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors
04:36

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors

Published on: October 17, 2025

450

Related Experiment Videos

Last Updated: Nov 10, 2025

Author Spotlight: Exploring the Lifespan Dynamics of Healthy Human Hematopoiesis
03:40

Author Spotlight: Exploring the Lifespan Dynamics of Healthy Human Hematopoiesis

Published on: December 8, 2023

1.5K
Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

421
Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors
04:36

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors

Published on: October 17, 2025

450

Area of Science:

  • Hematology
  • Oncology
  • Molecular Biology

Background:

  • Core binding factor (CBF) complexes, comprising CBFβ and RUNX, are vital for hematopoietic cell development.
  • Deregulation of CBF is implicated in acute myeloid leukemia (AML).
  • The CBFβ-SMMHC fusion oncogene, resulting from the inv(16) chromosomal abnormality, is a key driver in a subset of AML.

Purpose of the Study:

  • To review novel molecular mechanisms underlying CBFβ-SMMHC-driven leukemogenesis.
  • To highlight recent therapeutic advancements targeting CBFβ-SMMHC in inv(16) AML.

Main Methods:

  • Literature review of molecular mechanisms.
  • Analysis of recent therapeutic strategies and clinical trials.

Main Results:

  • CBFβ-SMMHC acts as a potent oncogene in hematopoietic stem cells, inducing AML.
  • Understanding its molecular pathways is crucial for targeted therapies.
  • Emerging therapies show promise in targeting CBFβ-SMMHC.

Conclusions:

  • CBFβ-SMMHC is a critical oncogenic driver in inv(16) AML.
  • Targeting CBFβ-SMMHC represents a promising therapeutic avenue for this AML subtype.
  • Further research into molecular mechanisms will refine treatment strategies.